ClinicaliQ Trial Snapshot
- A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism — Recruiting • Phase III • Diabetes / Metabolic • NCT06881992.
- Study testing whether ersodetug added to standard treatment reduces low blood sugar episodes in patients with insulin-producing tumours.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI). Conditions: Tumor Hyperinsulinism (Tumor HI) Interventions: Ersodetug Lead Sponsor: Rezolute Planned Enrollment: 16 participants